Session 404
Creating and Measuring Alliance Management Value

Demonstrating the value of alliance management is key in communicating alliance management achievements to senior management. The challenge is identifying the optimal metrics and collecting the data to create meaningful information to a variety of stakeholders. The purpose of this interactive workshop is to introduce options on how to verify value for alliance management and tools to measure the created value. Case examples will be presented of monetary and non-monetary value formation. This facilitated, collaborative workshop will focus on each table team first brainstorming on specific alliance management value generators, followed by team presentations on how to measure and communicate this value created.

Join colleagues and bring to this workshop metrics that demonstrate value in your organization, how the metrics are measured, and are being used to increase value recognition. In a group effort come away with:


Harm-Jan Borgeld, CSAP, PhD
Head of Alliance Management
Merck KGaA, Darmstadt, Germany

Harm-Jan Borgeld is leading the alliance management department at Merck KGaA. The department is responsible for the commercial, development, research, and selected regional alliances. Before heading the alliance management department, he was leading a project team that worked on developing a novel immunotherapy to treat cancer. He started his work at Merck in the licensing and business development department.

Prior to Merck, he was responsible for the business development activities of the Japanese firm, Kyorin Pharmaceuticals, in Europe. He received his MBA from the Rotterdam School of Management, the Netherlands / Haas Business School, US, and his PhD from the Faculty of Medicine, University of Nagoya, Japan, and graduated from the Wageningen University, the Netherlands.

Alexis Moran, CA-AM, PhD
Director, Merck KGaA-Pfizer Alliance Management
EMD Serono

Alexis is at EMD Serono where she manages the governance of the global strategic alliance between Merck KGaA and Pfizer, working across the clinical development and commercial organizations to facilitate progress and joint decision-making of the immuno-oncology alliance. Prior to joining EMD Serono, Alexis was at ImmunoGen, Inc. where she led oncology drug collaborations focused on biologics and novel ADC technology platforms, and advanced alliances from identification of lead candidates in discovery research to CMC development, manufacturing, and regulatory filings. Alexis previously worked in business development at Harvard's Office of Technology Development where she executed partnering activities for Harvard Medical School technologies and fostered industry interactions with faculty. She is a Biochemistry graduate from Bucknell University in Lewisburg and has a Ph.D. in Neuroscience from the University of Maryland School of Medicine, Baltimore.